China Pharma Holdings (CPHI) Change in Receivables (2010 - 2026)

China Pharma Holdings has reported Change in Receivables for 17 years, with the latest figure at $14019.0 in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables fell 91.49% year-over-year to $14019.0; the trailing twelve-month figure through Mar 2026 stood at -$13.4 million (down 2867.3% YoY), and the FY2025 full-year result was -$13.2 million, down 6780.77% from the prior year.
• Change in Receivables for Q1 2026 stood at $14019.0, up from -$13.5 million in the prior quarter.
• The five-year high for Change in Receivables was $434306.0 in Q1 2023, with the low at -$13.5 million in Q4 2025.
• Historically, Change in Receivables has averaged -$699321.9 across 5 years, with a median of $110025.0 in 2022.
• Annual changes were most pronounced in 2022 — Change in Receivables surged 578.17% — and 2025, when it sank 6444.99%.
• China Pharma Holdings' Change in Receivables stood at $107286.0 in 2022, then jumped by 239.52% to $364258.0 in 2023, then tumbled by 41.54% to $212942.0 in 2024, then slumped by 6444.99% to -$13.5 million in 2025, then soared by 100.1% to $14019.0 in 2026.
• The last three Change in Receivables figures came in at $14019.0 (Q1 2026), -$13.5 million (Q4 2025), and $117491.0 (Q3 2025), per Business Quant data.